About Us
Vision & Mission
To improve the healthcare journey and outcomes for individuals with complex, chronic diseases through innovative and actionable precision medicine testing solutions for immune-mediated inflammatory diseases.
We empower healthcare specialists with the ability to accelerate the achievement of sustained disease remission and disease control. Our precision-guided testing services enable clinicians to achieve improved outcomes, while supporting payer objectives of cost-effective care.
Mike Walther
Mike Walther, President and Board member. Mike has 30 years of expertise leading start up to established therapeutics, diagnostics and medical device businesses. Prior to joining…
Mike Walther
Mike Walther, President and Board member. Mike has 30 years of expertise leading start up to established therapeutics, diagnostics and medical device businesses. Prior to joining Prometheus in 2019 following the acquisition, Mike was General Manager of Aries Pharmaceuticals, having joined this start up as an Executive team member heading up Marketing and Commercial Strategy of the company’s portfolio of 5 pharmaceutical and medical device gastroenterology products. Mike has held senior leadership roles at Prometheus Laboratories (Nestle), Takeda Pharmaceuticals and TAP Pharmaceuticals, a joint venture between Takeda and Abbott Labs. In his career Mike has brought over 35 new products and indications to market.
Thierry Dervieux, PharmD, PhD
Thierry Dervieux, PharmD, PhD, Chief Scientific Officer, was most recently Chief Scientific Officer at Exagen Diagnostics, where he spent a decade building the Avise® portfolio of testing solutions…
Thierry Dervieux, PharmD, PhD
Thierry Dervieux, PharmD, PhD, Chief Scientific Officer, was most recently Chief Scientific Officer at Exagen Diagnostics, where he spent a decade building the Avise® portfolio of testing solutions. Prior to Exagen, Thierry was a founding executive of Proprius Pharmaceuticals (sold to Cypress Biosciences), where he started to develop a portfolio of precision guided dosing solutions for the management of AI gastrointestinal and rheumatic diseases. He is certified by the American Board of Clinical Chemistry in Clinical Chemistry and Molecular Diagnostics and holds PharmD and PhD degrees from Claude Bernard University. Thierry is the inventor or co-inventor on several patents and patent applications and has authored or co-authored over 70 publications.
Patricia Vasquez
Patricia Vasquez, Senior Vice President, Commercial and Corporate Development, most recently served as Vice President, Global Marketing, Business Development…
Patricia Vasquez, MBA
Patricia Vasquez, Senior Vice President, Commercial and Corporate Development, most recently served as Vice President, Global Marketing, Business Development and Service at Werfen, where she established technology and biomarker partnerships and led the successful global launch of diagnostic systems and novel tests for immune-mediated diseases. Prior to Werfen, Patricia was a founding executive of Proprius Pharmaceuticals (sold to Cypress Biosciences) where she served as Vice President, Marketing and Corporate Development, aggregated precision medicine and therapeutic assets, and launched the Avise precision medicine laboratory services in the rheumatology segment. Patricia holds a BA in Industrial/Organizational Psychology and an MBA from San Diego State University.
Brian Littlefied
Brian Littlefield, Senior Vice President of Information Services. Previously, Brian served at Exagen Diagnostics, where he established the IS function, and developed…
Brian Littlefied
Brian Littlefield, Senior Vice President of Information Services. Previously, Brian served at Exagen Diagnostics, where he established the IS function, and developed and implemented information systems that enabled the company’s rapid growth. Prior to Exagen, Brian was with Prometheus Laboratories in a similar role, having joined just following the formation of the company. During that time, he led and developed specialized systems to support proprietary diagnostics testing services and promotion of specialty therapeutics. Prior to that, Brian worked as a consultant with Deloitte, and as Director of Support Services at Quidel Corporation. He holds a BS in Biochemistry from Purdue University, and an MBA from Pepperdine University.
Lei Lu
Lei Lu is our Senior Vice President of Finance and Accounting. Lei previously served as Executive Vice President, Finance for HUYABIO International, where he was responsible for leading the financial strategy, FP&A, tax, treasury and accounting operations. Prior to HUYABIO, he was the Senior Vice President, Finance at ACEA Therapeutics (acquired by Sorrento Therapeutics) and ACEA Biosciences (acquired by Agilent). Before this, Lei was the Senior Vice President of Finance at Bird Rock Bio. He also held various senior financial management positions at Nokia, including head of finance/ global controller for their CDMA business unit. Preceding Nokia, he worked for Rockwell Automation, and Fiat Group (including Alfa Romeo UK, Case & New Holland) in various financial management positions. He has spent his professional career across the globe, working at companies in the US, UK, Italy, and China. Lei is a CPA. He earned his MBA from Leuven Business School at Katholieke Universiteit Leuven in Belgium and his BA in economics from Capital University of Economics and Business in China.
Andrew Shim
Andrew Shim, PharmD, JD, MAM, VP of Medical Affairs has broad medical affairs experience in medical communications, health economics and outcomes research, real world evidence…
Andrew Shim
Andrew Shim, PharmD, JD, MAM, VP of Medical Affairs has broad medical affairs experience in medical communications, health economics and outcomes research, real world evidence, phase 2-4 clinical studies, and field medical, as well as payer clinical policy and formulary management. He launched 20 drugs across 15 therapeutics including in GI and autoimmune, and managed health plan benefits to improve quality of care and cost trend. Most recently, he was the head of global HEOR and real-world evidence at Turning Point Therapeutics, and before that, Head of US & AAPAC Medical Affairs at Arena Pharmaceuticals. Other biopharma experiences include ACADIA, Pfizer, Hospira, Astellas, and Novartis. Andrew received his PharmD with honors from University of Minnesota where he is an Assistant Professor, a JD from Mitchell Hamline law school, and Masters in Management from Hamline University.
Michael Walsh
Michael Walsh, Chairman, most recently served as a Board Member for Lineagen, which provided specialized genetic testing for children with…
Michael Walsh
Michael Walsh, Chairman, most recently served as a Board Member for Lineagen, which provided specialized genetic testing for children with neurodevelopmental disorders. Previously, he served as Executive Vice President and Chief Commercial Officer at Cypress Biosciences, Inc. Prior to Cypress, Michael founded Proprius Pharmaceuticals, serving as the company’s President, CEO and Chairman until its acquisition by Cypress Biosciences. Michael co-founded Prometheus Laboratories, where he held the titles of President/COO, CEO and Executive Chairman of the Board. He also held senior commercial and operational roles at Quidel Corporation and La Jolla Pharmaceuticals.
Scott Glenn
Scott Glenn is Managing Partner of Windamere Venture Partners and Chairman of ReBalance Health. He founded and sold, or took public…
Scott Glenn
Scott Glenn is Managing Partner of Windamere Venture Partners and Chairman of ReBalance Health. He founded and sold, or took public, numerous biotech companies, including Prometheus Laboratories, Santarus, DexCom, Conception Technologies, NovaCardia, Cadence Pharmaceuticals, SkinMedica, VelosBio, Alastin Skincare and most recently Prometheus Biosciences.
Mike Walther
Mike Walther, President and Board member. Mike has 30 years of expertise leading start up to established therapeutics, diagnostics and medical device businesses…
Mike Walther
Mike Walther, President and Board member. Mike has 30 years of expertise leading start up to established therapeutics, diagnostics and medical device businesses. Prior to joining Prometheus in 2019 following the acquisition, Mike was General Manager of Aries Pharmaceuticals, having joined this start up as an Executive team member heading up Marketing and Commercial Strategy of the company’s portfolio of 5 pharmaceutical and medical device gastroenterology products. Mike has held senior leadership roles at Prometheus Laboratories (Nestle), Takeda Pharmaceuticals and TAP Pharmaceuticals, a joint venture between Takeda and Abbott Labs. In his career Mike has brought over 35 new products and indications to market.
Mark McKenna
Mark McKenna is the immediate past President, CEO and Chairman of Board of Prometheus Biosciences following the company’s acquisition by Merck…
Mark McKenna
Mark McKenna is the immediate past President, CEO and Chairman of Board of Prometheus Biosciences following the company’s acquisition by Merck. Prior to joining Prometheus Biosciences, he was President & CEO of Salix Pharmaceuticals, a wholly owned subsidiary of Bausch Health Companies, where he responsible for the company’s gastrointestinal franchise and leading the company through a series of key strategic acquisitions and new products launches.
William Sandborn, MD
Dr. William Sandborn is President and Chief Medical Officer of Ventyx Biosciences. Previously he was Chief Medical Officer…
William Sandborn, MD
Dr. William Sandborn is President and Chief Medical Officer of Ventyx Biosciences. Previously he was Chief Medical Officer at Shoreline Biosciences, and co-founded Shoreline Biosciences and Santarus. Dr. Sandborn served on the board of directors of Prometheus Biosciences. Dr. Sandborn has published over 939 peer reviewed articles including articles in the New England Journal of Medicine, Nature, Lancet, JAMA, Annals of Internal Medicine, and Gastroenterology. In 2019 he was awarded the Sherman Prize for his work in inflammatory bowel disease.
Rolf Benirschke
Rolf Benirschke is CEO of Legacy Health Strategies, a patient engagement company, and founder of The Grateful Patient Project. As a former NFL placekicker…
Rolf Benirschke
Rolf Benirschke is CEO of Legacy Health Strategies, a patient engagement company, and founder of The Grateful Patient Project. As a former NFL placekicker, his ten-year career was nearly derailed during his third season by a life-threatening battle with Crohn’s Disease. He has dedicated his life to supporting patients, built a patient engagement company, started an ostomy support program and is a respected leader and speaker in the health care industry.
James Laur
James Laur is Vice President, Intellectual Property at Cedars Sinai, leading the Technology Ventures Office. He also serves as Managing Director of…
James Laur
James Laur is Vice President, Intellectual Property at Cedars Sinai, leading the Technology Ventures Office. He also serves as Managing Director of Cedars-Sinai Health Ventures and the Cedars-Sinai Accelerator. He drives new business development and investment opportunities involving innovation and technology-related activities between Cedars-Sinai and its global partners.
Martin Hendrix
Martin Hendrix serves as the Global Head of Business Development and M&A for Nestlé Health Science, a division of Nestlé S.A. He is responsible for…
Martin Hendrix
Martin Hendrix serves as the Global Head of Business Development and M&A for Nestlé Health Science, a division of Nestlé S.A. He is responsible for all deal flow at Nestlé Health Science and also manages the company’s equity investments and VC portfolio. He has served on the board of directors of Prometheus Biosciences, Procise Dx, Axcella Health, Enterome, and Bodymed.
Dermot McGovern, MD, PhD
Dr. McGovern is a gastroenterologist and preeminent geneticist in the IBD field. Dr. McGovern completed his GI fellowship and obtained a PhD in complex disease genetics at the University of Oxford, England before moving to Cedars-Sinai …
Dermot McGovern, MD, PhD
Dr. McGovern is a gastroenterologist and preeminent geneticist in the IBD field. Dr. McGovern completed his GI fellowship and obtained a PhD in complex disease genetics at the University of Oxford, England before moving to Cedars-Sinai. Dr. McGovern is the Director of Translational Medicine at Cedars, co-Director of the Cedars-Sinai IBD repository (MIRIAD) and IBD Database and was recently appointed the Director of Precision Health at Cedars-Sinai. Dr. McGovern serves on both the Steering Committee of the NIDDK IBD Genetics Consortium, and on the Management Committee of the International IBD Genetics Consortium. Dr. McGovern is one of the founding members of Precision IBD, the predecessor of Prometheus Biosciences and serves as the consulting geneticist and provides input on the patient selection criteria.
Adam Cheifetz, MD
Adam S. Cheifetz is the Director of the Center for Inflammatory Bowel Disease and Medical Director of Infusion Services at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. He is also Director of the Harvard Medical School Gastroenterology…
Adam Cheifetz, MD
Adam S. Cheifetz is the Director of the Center for Inflammatory Bowel Disease and Medical Director of Infusion Services at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. He is also Director of the Harvard Medical School Gastroenterology Clerkship Elective and Assistant Director of the Advanced Fellowship in Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center.
Dr. Cheifetz graduated magna cum laude from Brown University before earning his M.D. from Cornell University Medical College. Dr. Cheifetz completed his internship and residency in Internal Medicine at Yale-New Haven Hospital and his fellowship in Gastroenterology at Yale University before serving as the Present-Levinson Fellow in Inflammatory Bowel Disease at the Mount Sinai Medical Center in New York City.
Dr. Cheifetz specializes in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. In addition to his clinical work, he is involved in multiple research projects relating to IBD and has published over 200 articles and chapters on the subject. His research currently focuses on optimizing the use of biologics through the proactive use of drug concentrations and antibodies and he has published extensively in this area. He is a fellow of the American Gastroenterological Association and American College of Gastroenterology.
Marla C Dubinsky, MD
Marla C Dubinsky is a Professor of Pediatrics and Medicine at the Icahn School of Medicine at Mount Sinai, New York, NY. Dr. Dubinsky received her medical degree from Queen’s University, Canada. She completed her pediatric residency at…
Marla C Dubinsky, MD
Marla C Dubinsky is a Professor of Pediatrics and Medicine at the Icahn School of Medicine at Mount Sinai, New York, NY. Dr. Dubinsky received her medical degree from Queen’s University, Canada. She completed her pediatric residency at Alberta Children’s Hospital, Calgary, Canada, and her clinical fellowship in gastroenterology and nutrition at Sainte-Justine Hospital at the University of Montreal, Canada. She then completed her research fellowship in IBD at Cedars-Sinai Medical Center in Los Angeles, CA, where she also served as the Director of the Pediatric IBD Center before going to Mount Sinai as the Chief of Pediatric Gastroenterology and Nutrition at the Mount Sinai Kravis Children’s Hospital. Dr. Dubinsky is also the Co-Director of the Susan and Leonard Feinstein IBD Clinical Center at Mount Sinai.
Her primary research focuses on the variability in clinical presentations, treatment responses and prognosis of early-onset IBD. She has lectured both nationally and internationally and has published in over 340 peer reviewed journals. In 2022, Dr. Dubinsky receive the Sherman Prize nationally recognizing her for excellence in Inflammatory Bowel Disease.
Dr. Dubinsky is also the Co-Founder of Trellus Health, Cornerstones Health, and WECARE.
Bincy P. Abraham, MD, MS, AGAF, FACG, FASGE
Bincy P. Abraham is the Distinguished Professor and Director of the Fondren Inflammatory Bowel Disease Program at the Underwood Digestive Diseases Center of Houston Methodist Hospital…
Bincy P. Abraham, MD, MS, AGAF, FACG, FASGE
Bincy P. Abraham is the Distinguished Professor and Director of the Fondren Inflammatory Bowel Disease Program at the Underwood Digestive Diseases Center of Houston Methodist Hospital. She is also the Program Director for the Gastroenterology Fellowship at Houston Methodist Hospital. She earned her medical degree from University of Texas Medical Branch, Galveston, TX, where she continued with residency training in internal medicine and fellowship in gastroenterology. During fellowship, she received specialized training in inflammatory bowel disease and earned her degree in Masters of Clinical Investigation. She also completed a National Visiting Fellow Inflammatory Bowel Disease Rotation program through the Crohn’s and Colitis Foundation in Cedars Sinai Hospital in Los Angeles. She has chaired the Southern Regional chapter of the CCFA Medical Advisory Committee, served as president of the Texas Gulf Coast Gastroenterology Society, is involved in national committees for and is a Fellow of the American College of Gastroenterology, American Gastroenterology Association, American Society of Gastrointestinal Endoscopy, and Crohn’s and Colitis Foundation.
William Sandborn, MD
Dr. William Sandborn is President and Chief Medical Officer of Ventyx Biosciences. Previously he was Chief Medical Officer at Shoreline Biosciences, and co-founded . Dr. Sandborn was a member of the board of directors for Prometheus…
William Sandborn, MD
Dr. William Sandborn is President and Chief Medical Officer of Ventyx Biosciences. Previously he was Chief Medical Officer at Shoreline Biosciences, and co-founded . Dr. Sandborn was a member of the board of directors for Prometheus Biosciences from 2017-2021 (IPO in 2021, acquired by Merck for $10.8 billon in 2023), and a co-founder of Santarus (founded 1998, IPO in 2004, acquired by Salix Pharmaceuticals for $2.6 billion in 2013). He completed medical school in 1987 and an internal medicine residency in 1990 at Loma Linda University in Loma Linda California, and gastroenterology fellowship at the Mayo Clinic in Rochester Minnesota in 1993. From 1993-2010, he was on the faculty of the Mayo Clinic, rising to Professor of Medicine and Vice Chairman of the Division of Gastroenterology and Hepatology. From 2011-2021 he was a Distinguished Professor of Medicine and Chief of the Division of Gastroenterology at the University of California San Diego (UCSD). Dr. Sandborn has published over 939 peer reviewed articles including articles in the New England Journal of Medicine, Nature, Lancet, JAMA, Annals of Internal Medicine, and Gastroenterology. His h index is 147. In 2019 he was awarded the Sherman Prize for his work in inflammatory bowel disease.